Growth factors mediated cell signalling in prostate cancer progression: Implications in discovery of anti-prostate cancer agents

Chemico-Biological Interactions

Volumn 240, Issue , 2015, Pages 120-133

  Joshi, Gaurav ^a   Singh, Pankaj Kumar ^a   Negi, Arvind ^a   Rana, Anil ^a   Singh, Sandeep ^a   Kumar, Raj ^a  

^a CENTRAL UNIVERSITY OF PUNJAB   (India)

Author keywords

Clinical reports; Growth factors; Inhibitors; Prostate cancer; Signalling

Indexed keywords

ABARELIX; ABIRATERONE ACETATE; ALFUZOSIN; AMUVATINIB; ANTINEOPLASTIC AGENT; CABAZITAXEL; DEATH RECEPTOR; DEGARELIX; ENZALUTAMIDE; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FLUTAMIDE; GOSERELIN; GROWTH FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTEGRIN; JANUS KINASE; LEUPRORELIN; MICRORNA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RADIUM CHLORIDE RA 223; SIPULEUCEL T; SOMATOMEDIN C RECEPTOR; SONIC HEDGEHOG PROTEIN; TRANSFORMING GROWTH FACTOR ALPHA; TRIPTORELIN; UNINDEXED DRUG; WNT PROTEIN; SIGNAL PEPTIDE;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BONE METASTASIS; CANCER GROWTH; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SURVIVAL; CARCINOGENESIS; CELL MIGRATION; CELL MOTILITY; DISEASE ASSOCIATION; DRUG APPROVAL; DRUG EFFICACY; DRUG STRUCTURE; HUMAN; INFLAMMATION; INTRACELLULAR SIGNALING; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TUMOR GROWTH; UPREGULATION; DRUG DEVELOPMENT; DRUG EFFECTS; MALE; METABOLISM; PROSTATIC NEOPLASMS;

ANTINEOPLASTIC AGENTS; DRUG DISCOVERY; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84941362918     PISSN: 00092797     EISSN: 18727786     Source Type: Journal    
DOI: 10.1016/j.cbi.2015.08.009     Document Type: Review

References (154)

1. G.J. Alivizatos, and P.A. Pavlakis Introduction to Prostate Cancer. Imaging in Clinical Oncology 2014 Springer 553 557
2. M.M. Center, A. Jemal, J. Lortet-Tieulent, E. Ward, J. Ferlay, O. Brawley, and et al. International variation in prostate cancer incidence and mortality rates Eur. Urol. 61 6 2012 1079 1092
3. M. Dean, and H. Lou Genetics and genomics of prostate cancer Asian J. Androl. 15 3 2013 309 313
4. H.A. Vargas, J. Chaim, and O. Akin Prostate Cancer Imaging. Atlas of Genitourinary Oncological Imaging 2013 Springer 95 120
5. P.D. Baade, D.R. Youlden, S.M. Cramb, J. Dunn, and R.A. Gardiner Epidemiology of prostate cancer in the Asia-Pacific region Prostate Int. 1 2 2013 47
6. W.G. Nelson, K.S. Sfanos, A.M. DeMarzo, and S. Yegnasubramanian Prostate Inflammation and Prostate Cancer. Management of Prostate Cancer 2013 Springer 103 115
7. J. Felgueiras, Silva Jv, and M. Fardilha Prostate cancer: the Need for Biomarkers and New Therapeutic Targets 2013
8. M.B. Sporn New agents for chemoprevention of prostate cancer Eur. Urol. 35 5-6 2012 420 423
9. R. Amato, M. Stepankiw, and P. Gonzales A phase II trial of androgen deprivation therapy (ADT) plus chemotherapy as initial treatment for local failures or advanced prostate cancer Cancer Chemother. Pharmacol. 2013 1 6
10. A.A. Shafi, A.E. Yen, and N.L. Weigel Androgen receptors in hormone-dependent and castration-resistant prostate cancer Pharmacol. Ther. 140 3 2013 223 238
11. X. Yuan, C. Cai, S. Chen, Z. Yu, and S. Balk Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis Oncogen 33 22 2014 2815 2825
12. P.S. Gowda, J.D. Deng, S. Mishra, A. Bandyopadhyay, S. Liang, S. Lin, and et al. Inhibition of hedgehog and androgen receptor signaling pathways produced synergistic suppression of castration-resistant prostate cancer progression Mol. Cancer Res. 11 11 2013 1448 1461
13. A. Bahl, S. Oudard, B. Tombal, M. Ozguroglu, S. Hansen, I. Kocak, and et al. Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial Ann. Oncol. 00 2013 1 7
14. Ö Acar, T. Esen, and N.A. Lack New therapeutics to treat castrate resistant prostate cancer Sci. World J. 2013
15. J.J. Alumkal, J.N. Graff, and T.M. Beer Targeted therapy in prostate cancer: is there hope beyond the androgen receptor? Oncology 27 7 2013
16. G.J. Kelloff, R. Lieberman, V.E. Steele, C.W. Boone, R.A. Lubet, L. Kopelovitch, and et al. Chemoprevention of prostate cancer: concepts and strategies Eur. Urol. 35 5-6 2012 342 350
17. M. Malhotra, R. Dhingra, T. Sharma, A. Deep, B. Narasimhan, P. Phogat, and et al. Cabazitaxel: a novel drug for hormone-refractory prostate cancer Mini Rev. Med. Chem. 13 6 2013 915 920
18. F. Calcagno, T. Nguyen, E. Dobi, C. Villanueva, E. Curtit, S. Kim, and et al. Safety and efficacy of cabazitaxel in the docetaxel-treated patients with hormone-refractory prostate cancer Clin. Med. Insights Oncol. 7 2013 1
19. B.R. Cassileth, E.J. Seidmon, M.S. Soloway, H.I. Hait, N.J. Vogelzang, G.T. Kennealey, and et al. Patients' choice of treatment in stage D prostate cancer Urology 33 5 1989 57 62
20. M.S. Soloway, K. Pareek, R. Sharifi, Z. Wajsman, D. Mcleod, Dp Wood Jr., and et al. Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results J. Urol. 167 1 2002 112 116
21. M.J. Zelefsky, S.A. Leibel, C.M. Burman, G.J. Kutcher, A. Harrison, L. Happersett, and et al. Neoadjuvant hormonal therapy improves the therapeutic ratio in patients with bulky prostatic cancer treated with three-dimensional conformal radiation therapy Int. J. Radiat. Oncol. Biol. Phys. 29 4 1994 755 761
22. M.S. Soloway, R. Sharifi, Z. Wajsman, D. McLeod, and D.P. Wood Jr. Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockage in clinical stage B2 (T2bNxM0) prostate cancer J. Urol. 154 2 1995 424 428
23. D.G. Mcleod Hormonal therapy: historical perspective to future directions Urology 61 2 2003 3 7
24. J.E. Fowler Jr., M. Flanagan, D.M. Gleason, I.W. Klimberg, J.E. Gottesman, and R. Sharifi Evaluation of an implant that delivers leuprolide for 1 year for the palliative treatment of prostate cancer Urology 55 5 2000 639 642
25. R. Berges, and U. Bello Effect of a new leuprorelin formulation on testosterone levels in patients with advanced prostate cancer Curr. Med. Res. Opin. 22 4 2006 649 655
26. G.K. Reddy, V.K. Jain, and O. Sartor Abarelix (Plenaxis™): a gonadotropin-releasing hormone antagonist for medical castration in patients with advanced prostate cancer Clin. Prostate Cancer 2 4 2004 209 211
27. B. Yang Drug profile: UroXatral Discov. Med. 2 17 2009 12 13
28. C. Doehn, M. Sommerauer, and D. Jocham Degarelix for Prostate Cancer 2009 851 860
29. M.A. Cheever, and C.S. Higano Provenge (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine Clin. Cancer Res. 17 11 2011 3520 3526
30. C.J. Paller, and E.S. Antonarakis Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer Drug Des. Dev. Ther. 5 2011 117
31. E.S. Antonarakis, and M.A. Eisenberger Expanding treatment options for metastatic prostate cancer New Engl. J. Med. 364 21 2011 2055
32. J. Hoffman-Censits, and W.K. Kelly Enzalutamide: a novel antiandrogen for patients with castrate-resistant prostate cancer Clin. Cancer Res. 19 6 2013 1335 1339
33. P.G. Kluetz, W. Pierce, V.E. Maher, H. Zhang, S. Tang, P. Song, and et al. Radium Ra 223 dichloride injection: US food and drug administration drug approval summary Clin. Cancer Res. 20 1 2014 9 14
34. L. Reddy, B. Odhav, and K. Bhoola Natural products for cancer prevention: a global perspective Pharmacol. Ther. 99 1 2003 1 13
35. D.L. Bemis, A.E. Katz, and R. Buttyan Clinical Trials of Natural Products as Chemopreventive Agents for Prostate Cancer 2006 1191 1200
36. N.P. Gullett, A. Ruhul Amin, S. Bayraktar, J.M. Pezzuto, D.M. Shin, F.R. Khuri, and et al. Cancer prevention with Natural Compounds. Seminars in Oncology vol. 37, no. 3 2010 258 281
37. F.H. Sarkar, Y. Li, Z. Wang, and D. Kong Novel targets for prostate cancer chemoprevention Endocrine-related cancer 17 3 2010 R195 R212
38. C.-M. Hung, Y.-H. Su, H.-Y. Lin, J.-N. Lin, L.-C. Liu, C.-T. Ho, and et al. Demethoxycurcumin modulates prostate cancer cell proliferation via AMPK-induced down-regulation of HSP70 and EGFR J. Agric. food Chem. 60 34 2012 8427 8434
39. T. Schlomm, P. Kirstein, L. Iwers, B. Daniel, T. Steuber, J. Walz, and et al. Clinical significance of epidermal growth factor receptor protein overexpression and gene copy number gains in prostate cancer Clin. Cancer Res. 13 22 2007 6579 6584
40. M. Karlou, V. Tzelepi, and E. Efstathiou Therapeutic targeting of the prostate cancer microenvironment Nat. Rev. Urol. 7 9 2010 494 509
41. Y. Gan, C. Shi, L. Inge, M. Hibner, J. Balducci, and Y. Huang Differential roles of ERK and Akt pathways in regulation of EGFR-mediated signaling and motility in prostate cancer cells Oncogene 29 35 2010 4947 4958
42. S. Xu, and Z. Weihua Loss of EGFR induced autophagy sensitizes hormone refractory prostate cancer cells to adriamycin The. Prostate 71 11 2011 1216 1224
43. Y.E. Whang, A.J. Armstrong, W.K. Rathmell, P.A. Godley, W.Y. Kim, R.S. Pruthi, and et al. A Phase II Study of Lapatinib, a Dual EGFR and HER-2 Tyrosine Kinase Inhibitor, in Patients with Castration-resistant Prostate cancer. Urologic Oncology: Seminars and Original Investigations vol. 31, No. 1 2013 82 86
44. J. Ren, L.R. Bollu, F. Su, G. Gao, L. Xu, W.C. Huang, and et al. EGFR-SGLT1 interaction does not respond to EGFR modulators, but inhibition of SGLT1 sensitizes prostate cancer cells to EGFR tyrosine kinase inhibitors Prostate 73 13 2013 1453 1461
45. P. Hammarsten, A. Karalija, A. Josefsson, S.H. Rudolfsson, P. Wikström, L. Egevad, and et al. Low levels of phosphorylated epidermal growth factor receptor in nonmalignant and malignant prostate tissue predict favorable outcome in prostate cancer patients Clin. Cancer Res. 16 4 2010 1245 1255
46. I. Abasolo, L.M. Montuenga, and A. Calvo Adrenomedullin prevents apoptosis in prostate cancer cells Regul. Pept. 133 1 2006 115 122
47. F. Satoh, H. Mimata, T. Nomura, Y. Fujita, T. Shin, S. Sakamoto, and et al. Autocrine expression of neurotrophins and their receptors in prostate cancer Int. J. Urol. 8 7 2001 S28 S34
48. Z. Wang, Y. Li, S. Banerjee, D. Kong, A. Ahmad, V. Nogueira, and et al. Down-regulation of Notch-1 and Jagged-1 inhibits prostate cancer cell growth, migration and invasion, and induces apoptosis via inactivation of Akt, mTOR, and NF-κB signaling pathways J. Cell. Biochem. 109 4 2010 726 736
49. E.D. Crawford Understanding the epidemiology, natural history, and key pathways involved in prostate cancer Urology 73 5 2009 S4 S10
50. H. Yamamoto, N. Oue, A. Sato, Y. Hasegawa, A. Matsubara, W. Yasui, and et al. Wnt5a signaling is involved in the aggressiveness of prostate cancer and expression of metalloproteinase Oncogene 29 14 2010 2036 2046
51. A. Zoubeidi, A. Zardan, R.M. Wiedmann, J. Locke, E. Beraldi, L. Fazli, and et al. Hsp27 promotes insulin-like growth factor-I survival signaling in prostate cancer via p90Rsk-dependent phosphorylation and inactivation of BAD Cancer Res. 70 6 2010 2307 2317
52. S. Kojima, M. Inahara, H. Suzuki, T. Ichikawa, and Y. Furuya Implications of insulin-like growth factor-I for prostate cancer therapies Int. J. Urol. 16 2 2009 161 167
53. F. Saad, and A. Lipton SRC kinase inhibition: targeting bone metastases and tumor growth in prostate and breast cancer Cancer Treat. Rev. 36 2 2010 177 184
54. A.L. Shodeinde, and B.E. Barton Potential use of STAT3 inhibitors in targeted prostate cancer therapy: future prospects OncoTargets Ther. 5 2012 119
55. M. Pi, and L.D. Quarles GPRC6A regulates prostate cancer progression Prostate 72 4 2012 399 409
56. W. Qi, L.S. Cooke, A. Stejskal, C. Riley, K.D. Croce, J.W. Saldanha, and et al. MP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancer BMC Cancer 9 1 2009 142
57. B.B. Hafeez, W. Zhong, J. Weichert, N.E. Dreckschmidt, M.S. Jamal, and A.K. Verma Genetic ablation of PKC epsilon inhibits prostate cancer development and metastasis in transgenic mouse model of prostate adenocarcinoma Cancer Res. 71 6 2011 2318 2327
58. W. Chen, D. Xie, J. Hou, H. Long, G. Li, J. Pu, and et al. Inhibition of EGFR signaling in prostate cancer treated with EGFR siRNA and Gefitinib Life Sci. J. 9 2 2012 366 377 359(4)
59. C. Borghese, L. Cattaruzza, E. Pivetta, N. Normanno, A. De Luca, M. Mazzucato, and et al. Gefitinib inhibits the cross-talk between mesenchymal stem cells and prostate cancer cells leading to tumor cell proliferation and inhibition of docetaxel activity J. Cell. Biochem. 114 5 2013 1135 1144
60. M. Addepalli, K. Ray, B. Kumar, and R. Ramnath RNAi-mediated knockdown of AURKB and EGFR shows enhanced therapeutic efficacy in prostate tumor regression Gene Ther. 17 3 2009 352 359
61. S. Sharad, L.N. Singhal, Jyotsana Singhal, and Sanjay Awasthi Role of a novel flavonoid enriched in ocimum sanctum linn for prostate cancer chemoprevention and therapy Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 31March-4 April 2012 Cancer Research Chicago, Philadelphia
62. J.M. Drake, N.A. Graham, T. Stoyanova, A. Sedghi, A.S. Goldstein, H. Cai, and et al. Oncogene-specific activation of tyrosine kinase networks during prostate cancer progression Proc. Natl. Acad. Sci. 109 5 2012 1643 1648
63. F.G. Rick, A.V. Schally, L. Szalontay, N.L. Block, K. Szepeshazi, M. Nadji, and et al. Antagonists of growth hormone-releasing hormone inhibit growth of androgen-independent prostate cancer through inactivation of ERK and Akt kinases Proc. Natl. Acad. Sci. 109 5 2012 1655 1660
64. S. Feng, L. Shao, W. Yu, P. Gavine, and M. Ittmann Targeting fibroblast growth factor receptor signaling inhibits prostate cancer progression Clin. Cancer Res. 18 14 2012 3880 3888
65. L. Muñoz-Moreno, M.I. Arenas, A.V. Schally, A.B. Fernández-Martínez, E. Zarka, M. González-Santander, and et al. Inhibitory effects of antagonists of growth hormone-releasing hormone on growth and invasiveness of PC3 human prostate cancer Int. J. Cancer 132 4 2013 755 765
66. Y. Yarden, and A. Ullrich Growth factor receptor tyrosine kinases Annu. Rev. Biochem. 57 1 1988 443 478
67. H.W. Longfellow Growth Factor Signaling Pathways. The Molecular Biology of Cancer: a Bridge from Bench to Bedside 2013 160
68. R. Perona Cell signalling: growth factors and tyrosine kinase receptors Clin. Transl. Oncol. 8 2 2006 77 82
69. C. Berenguer-Daizé, F. Boudouresque, C. Bastide, A. Tounsi, Z. Benyahia, J. Acunzo, and et al. Adrenomedullin blockade suppresses growth of human hormone-independent prostate tumor xenograft in mice Clin. Cancer Res. 19 22 2013 6138 6150
70. P. Wikström, T. Granfors, L. Egevad, P. Stattin, and A. Bergh Angiopoietin 2 expression is related to histological grade, vascular density, metastases, and outcome in prostate cancer Prostate 62 4 2005 394 399
71. J. Banyard, and B.R. Zetter The role of cell motility in prostate cancer Cancer Metastasis Rev. 17 4 1998 449 458
72. H. Nishimori, S. Ehata, H.I. Suzuki, Y. Katsuno, and K. Miyazono Prostate cancer cells and bone stromal cells mutually interact with each other through bone morphogenetic protein-mediated signals J. Biol. Chem. 287 24 2012 20037 20046
73. G. Di Lorenzo, G. Tortora, F.P. D'Armiento, G. De Rosa, S. Staibano, R. Autorino, and et al. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer Clin. Cancer Res. 8 11 2002 3438 3444
74. M.O. Arcasoy, K. Amin, R.T. Vollmer, X. Jiang, W. Demark-Wahnefried, and Z.A. Haroon Erythropoietin and erythropoietin receptor expression in human prostate cancer Mod. Pathol. 18 3 2004 421 430
75. C.I. Rivas, J.C. Vera, F. Delgado-López, M.L. Heaney, V.H. Guaiquil, R.H. Zhang, and et al. Expression of granulocyte-macrophage colony-stimulating factor receptors in human prostate cancer Blood 91 3 1998 1037 1043
76. S.M. Bokobza, L. Ye, H.G. Kynaston, and W.G. Jiang Growth and differentiation factor-9 promotes adhesive and motile capacity of prostate cancer cells by up-regulating FAK and Paxillin via Smad dependent pathway Oncol. Rep. 24 6 2010 1653 1659
77. K. Yasuda, A. Komiya, A. Watanabe, A. Morii, T. Oya, O. Nagakawa, and et al. Expression of hepatocyte growth factor activator inhibitor type-1 (HAI-1) in prostate cancer Anticancer Res. 33 2 2013 575 581
78. K.K. Tsilidis, R.C. Travis, P.N. Appleby, N.E. Allen, S. Lindstrom, D. Albanes, and et al. Insulin-like growth factor pathway genes and blood concentrations, dietary protein and risk of prostate cancer in the NCI Breast and Prostate Cancer Cohort Consortium (BPC3) Int. J. Cancer 133 2 2013 495 504
79. A. Negi, P. Ramarao, and R. Kumar Recent advancements in small molecule inhibitors of insulin-like growth factor-1 receptor (IGF-1R) tyrosine kinase as anticancer agents Mini Rev. Med. Chem. 13 5 2013 653 681
80. S.L. Schor, I.R. Ellis, S.J. Jones, R. Baillie, K. Seneviratne, J. Clausen, and et al. Migration-stimulating factor a genetically truncated onco-fetal fibronectin isoform expressed by carcinoma and tumor-associated stromal cells Cancer Res. 63 24 2003 8827 8836
81. L. Ye, J. Lewis-Russell, H. Kynaston, and W. Jiang Bone Morphogenetic Proteins and their Receptor Signaling in Prostate Cancer 2007 ISSN: 0213-3911
82. V. Anagnostopoulou, I. Pediaditakis, S. Alkahtani, S.A. Alarifi, E.-M. Schmidt, F. Lang, and et al. Differential effects of dehydroepiandrosterone and testosterone in prostate and colon cancer cell apoptosis: the role of Nerve Growth Factor (NGF) Receptors Endocrinology 154 7 2013 2446 2456
83. A. Rosenberg, and P. Mathew Imatinib and prostate cancer: lessons learned from targeting the platelet-derived growth factor receptor Expert Opin. Investig. Drugs 22 6 2013 787 794
84. C. Erickson-Miller, K. Pillarisetti, J. Kirchner, L. Ottesen, Y.M. Kamel, Y. Liu, and et al. Thrombopoietin Expression and Effects of Eltrombopag in Prostate, Breast, Lung, and Ovarian Solid Tumors 2010 Journal of clinical oncology (Meeting Abstracts)
85. G. Wilding, E. Valverius, C. Knabbe, and E.P. Gelmann Role of transforming growth factor-α in human prostate cancer cell growth Prostate 15 1 1989 1 12
86. C. Lee, S.M. Sintich, E.P. Mathews, A.H. Shah, S.D. Kundu, K.T. Perry, and et al. Transforming growth factor-β in benign and malignant prostate Prostate 39 4 1999 285 290
87. P. Szlosarek, K.A. Charles, and F.R. Balkwill Tumour necrosis factor-α as a tumour promoter Eur. J. Cancer 42 6 2006 745 750
88. K. Eisermann, C.J. Broderick, A. Bazarov, M.M. Moazam, and G.C. Fraizer Androgen up-regulates vascular endothelial growth factor expression in prostate cancer cells via an Sp1 binding site Mol. Cancer 12 1 2013 7
89. S. Thiele, M. Rauner, C. Goettsch, T. Rachner, P. Benad, S. Füssel, and et al. WNT pathway in prostate cancer: expression profile and regulation by bisphosphonates Age 8 1.4 2012 65.5-1.7
90. K. Matsumoto, K. Suzuki, H. Koike, M. Hasumi, H. Matsui, H. Okugi, and et al. Placental growth factor gene expression in human prostate cancer and benign prostate hyperplasia Anticancer Res. 23 5A 2003 3767 3773
91. F.L. Carvalho, B. Simons, and D.M. Berman Abstract B56: notch signaling in prostate cancer progression Cancer Res. 72 4 Supplement 2012 B56 B
92. J.E. Lisle, I. Mertens-Walker, R. Rutkowski, A.C. Herington, and S.-A. Stephenson Eph receptors and their ligands: promising molecular biomarkers and therapeutic targets in prostate cancer Biochimica Biophysica Acta (BBA)-Reviews Cancer 1835 2 2013 243 257
93. Z. Culig, and M. Puhr Interleukin-6: a multifunctional targetable cytokine in human prostate cancer Mol. Cell. Endocrinol. 360 1 2012 52 58
94. E. Richter, S. Srivastava, and A. Dobi Androgen receptor and prostate cancer Prostate Cancer Prostatic Dis. 10 2 2007 114 118
95. B.J. Feldman, and D. Feldman The development of androgen-independent prostate cancer Nat. Rev. Cancer 1 1 2001 34 45
96. J.T. Buijs, N.V. Henriquez, P.G. van Overveld, G. van der Horst, P. Ten Dijke, and G. van der Pluijm TGF-β and BMP7 interactions in tumour progression and bone metastasis Clin. Exp. Metastasis 24 8 2007 609 617
97. T.D. Chung, J.J. Yu, M.T. Spiotto, M. Bartkowski, and J.W. Simons Characterization of the role of IL-6 in the progression of prostate cancer Prostate 38 3 1999 199 207
98. D.F. Jarrard, B.F. Blitz, R.C. Smith, B.L. Patai, and D.B. Rukstalis Effect of epidermal growth factor on prostate cancer cell line PC3 growth and invasion Prostate 24 1 1994 46 53
99. J.M. Chan, M.J. Stampfer, J. Ma, P. Gann, J.M. Gaziano, M. Pollak, and et al. Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer J. Natl. Cancer Inst. 94 14 2002 1099 1106
100. M.W. Jackson, J.M. Bentel, and W.D. Tilley Vascular endothelial growth factor (VEGF) expression in prostate cancer and benign prostatic hyperplasia J. Urol. 157 6 1997 2323 2328
101. K. Sahadevan, S. Darby, H. Leung, M. Mathers, C. Robson, and V. Gnanapragasam Selective over-expression of fibroblast growth factor receptors 1 and 4 in clinical prostate cancer J. Pathol. 213 1 2007 82 90
102. C.W. Gregory, B. He, R.T. Johnson, O.H. Ford, J.L. Mohler, F.S. French, and et al. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy Cancer Res. 61 11 2001 4315 4319
103. M.-L. Zhu, and N. Kyprianou Androgen receptor and growth factor signaling cross-talk in prostate cancer cells Endocrine-related Cancer 15 4 2008 841 849
104. A.R. Reynolds, and N. Kyprianou Growth factor signalling in prostatic growth: significance in tumour development and therapeutic targeting Br. J. Pharmacol. 147 S2 2006 S144 S152
105. N. Tebbutt, M.W. Pedersen, and T.G. Johns Targeting the ERBB family in cancer: couples therapy Nat. Rev. Cancer 13 9 2013 663 673
106. A. Tomas, C.E. Futter, and E.R. Eden EGF receptor trafficking: consequences for signaling and cancer Trends Cell Biol. 24 1 2013 26 34
107. Y. Huang, and Y. Chang Epidermal Growth Factor Receptor (EGFR) Phosphorylation, Signaling and Trafficking in Prostate cancer 2011 INTECH Open Access Publisher
108. L. Zhang, F. Zhou, and P. ten Dijke Signaling interplay between transforming growth factor-β receptor and PI3K/AKT pathways in cancer Trends Biochem. Sci. 38 12 2013 612 620
109. C. Tournier The 2 faces of JNK signaling in cancer Genes & Cancer 4 9-10 2013 397 400
110. L. Rauhala, L. Hämäläinen, P. Salonen, G. Bart, M. Tammi, S. Pasonen-Seppänen, and et al. Low dose ultraviolet B irradiation increases hyaluronan synthesis in epidermal keratinocytes via sequential induction of hyaluronan synthases Has1-3 mediated by p38 and Ca2+/calmodulin-dependent protein kinase II (CaMKII) signaling J. Biol. Chem. 288 25 2013 17999 18012
111. X. Dolcet, D. Llobet, J. Pallares, and X. Matias-Guiu NF-kB in development and progression of human cancer Virchows Arch. 446 5 2005 475 482
112. B. Hoesel, and J.A. Schmid The complexity of NF-κB signaling in inflammation and cancer Mol. Cancer 12 86 2013 1 15
113. L. Zhang, L. Shao, C.J. Creighton, Y. Zhang, L. Xin, M. Ittmann, and et al. Function of phosphorylation of NF-kB p65 ser536 in prostate cancer oncogenesis Oncotarget 6 8 2015 6281 6294
114. L. Zhang, S. Altuwaijri, F. Deng, L. Chen, P. Lal, U.K. Bhanot, and et al. NF-κB regulates androgen receptor expression and prostate cancer growth Am. J. Pathol. 175 2 2009 489 499
115. Vara JÁF, E. Casado, J. de Castro, P. Cejas, C. Belda-Iniesta, and M. González-Barón PI3K/Akt signalling pathway and cancer Cancer Treat. Rev. 30 2 2004 193 204
116. N. Gao, Z. Zhang, B.-H. Jiang, and X. Shi Role of PI3K/AKT/mTOR signaling in the cell cycle progression of human prostate cancer Biochem. Biophys. Res. Commun. 310 4 2003 1124 1132
117. F. Chang, J. Lee, P. Navolanic, L. Steelman, J. Shelton, W. Blalock, and et al. Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy Leukemia 17 3 2003 590 603
118. S.H. Aghaee-Bakhtiari, E. Arefian, M. Naderi, F. Noorbakhsh, V. Nodouzi, M. Asgari, and et al. MAPK and JAK/STAT pathways targeted by miR-23a and miR-23b in prostate cancer: computational and in vitro approaches Tumor Biol. 2015 1 10
119. J.S. Rawlings, K.M. Rosler, and D.A. Harrison The JAK/STAT signaling pathway J. Cell Sci. 117 8 2004 1281 1283
120. Y. Cao, K. Nimptsch, I.M. Shui, E.A. Platz, K. Wu, M.N. Pollak, and et al. Prediagnostic plasma IGFBP-1, IGF-1 and risk of prostate cancer Int. J. Cancer 136 10 2015 2418 2426
121. M. Yu, G.A. Smolen, D.A. Haber, and S. Maheswaran The role of growth factor-induced changes in cell fate in prostate cancer progression Syst. Biol. Cancer 2015 361
122. E.H. Danen Integrin signaling as a cancer drug target ISRN Cell Biol. 2013 2013
123. P. Chin, J. Dickinson, and A. Holloway Integrins in Prostate Cancer Invasion and Metastasis 2013
124. R. Jin, J.A. Sterling, J.R. Edwards, D.J. DeGraff, C. Lee, S.I. Park, and et al. Activation of NF-kappa B signaling promotes growth of prostate cancer cells in bone PloS One 8 4 2013 e60983
125. I. Bisson, and D.M. Prowse WNT signaling regulates self-renewal and differentiation of prostate cancer cells with stem cell characteristics Cell Res. 19 6 2009 683 697
126. P. Polakis Wnt signaling and cancer Genes & Dev. 14 15 2000 1837 1851
127. M. Verras, and Z. Sun Roles and regulation of Wnt signaling and β-catenin in prostate cancer Cancer Lett. 237 1 2006 22 32
128. G. Yardy, and S. Brewster Wnt signalling and prostate cancer Prostate Cancer Prostatic Dis. 8 2 2005 119 126
129. A.R. i Altaba, P. Sánchez, and N. Dahmane Gli and hedgehog in cancer: tumours, embryos and stem cells Nat. Rev. Cancer 2 5 2002 361 372
130. G. Shaw, A.M. Price, E. Ktori, I. Bisson, P.E. Purkis, S. McFaul, and et al. Hedgehog signalling in androgen independent prostate cancer Eur. Urol. 54 6 2008 1333 1343
131. S. Ray, J.G. Hissong, M. Oancea, and A. Almasan Expression and Regulation of Death Receptors in Multiple Myeloma and Prostate Carcinoma. Death Receptors in Cancer Therapy 2005 Springer 281 296
132. H.F. O'Kane, C.J. Watson, S.R. Johnston, I. Petak, R. William, G. Watson, and et al. Targeting death receptors in bladder, prostate and renal cancer J. Urol. 175 2 2006 432 438
133. M.E. Grossmann, H. Huang, and D.J. Tindall Androgen receptor signaling in androgen-refractory prostate cancer J. Natl. Cancer Inst. 93 22 2001 1687 1697
134. O. Guérin, J.L. Fischel, J.-M. Ferrero, A. Bozec, and G. Milano EGFR targeting in hormone-refractory prostate cancer: current appraisal and prospects for treatment Pharmaceuticals 3 7 2010 2238 2247
135. L. Leotoing, M. Manin, D. Monte, S. Baron, Y. Communal, C. Lours, and et al. Crosstalk between androgen receptor and epidermal growth factor receptor-signalling pathways: a molecular switch for epithelial cell differentiation J. Mol. Endocrinol. 39 2 2007 151 162
136. Y. Li, and F.H. Sarkar Inhibition of nuclear factor κB activation in PC3 cells by genistein is mediated via Akt signaling pathway Clin. Cancer Res. 8 7 2002 2369 2377
137. S. Srinivasan, R. Kumar, S. Koduru, A. Chandramouli, and C. Damodaran Inhibiting TNF-mediated signaling: a novel therapeutic paradigm for androgen independent prostate cancer Apoptosis 15 2 2010 153 161
138. K.H. Khan, T.A. Yap, L. Yan, and D. Cunningham Targeting the PI3K-AKT-mTOR signaling network in cancer Chin. J. Cancer 32 5 2013 253
139. G. Miklossy, T.S. Hilliard, and J. Turkson Therapeutic modulators of STAT signalling for human diseases Nat. Rev. Drug Discov. 12 8 2013 611 629
140. G. Rodríguez-Berriguete, B. Fraile, P. Martínez-Onsurbe, G. Olmedilla, R. Paniagua, and M. Royuela MAP kinases and prostate cancer J. Signal Transduct. 2011 2012
141. W. Kolch Coordinating ERK/MAPK signalling through scaffolds and inhibitors Nat. Rev. Mol. cell Biol. 6 11 2005 827 837
142. S. Shukla, and S. Gupta Apigenin suppresses insulin-like growth factor I receptor signaling in human prostate cancer: an in vitro and in vivo study Mol. Carcinog. 48 3 2009 243 252
143. R. Malaguarnera, A. Sacco, A. Morcavallo, S. Squatrito, A. Migliaccio, A. Morrione, and et al. Metformin inhibits androgen-induced IGF-IR up-regulation in prostate cancer cells by disrupting membrane-initiated androgen signaling Endocrinology 155 4 2014 1207 1221
144. W. Lu, H.N. Tinsley, A. Keeton, Z. Qu, G.A. Piazza, and Y. Li Suppression of Wnt/β-catenin signaling inhibits prostate cancer cell proliferation Eur. J. Pharmacol. 602 1 2009 8 14
145. R.T. Hillman, B.Y. Feng, J. Ni, W.-M. Woo, L. Milenkovic, M.G.H. Gephart, and et al. Neuropilins are positive regulators of Hedgehog signal transduction Genes & Dev. 25 22 2011 2333 2346
146. R. Mody Targeting death receptors: is this trail still hot? Transl. Pediatr. 2 2 2013 66 69
147. R. Hu, Q. Du, X. Yin, J. Li, T. Wang, and L. Zhang Agonist antibody activates death receptor 6 downstream signaling involving TRADD recruitment FEBS Lett. 588 3 2014 401 407
148. I. Schmitz, S. Kirchhoff, and P.H. Krammer Regulation of death receptor-mediated apoptosis pathways Int. J. Biochem. Cell Biol. 32 11 2000 1123 1136
149. A. Hata, and J. Lieberman Dysregulation of microRNA biogenesis and gene silencing in cancer Sci. Signal. 8 368 2015 re3
150. A. Esquela-Kerscher, and F.J. Slack Oncomirs - microRNAs with a role in cancer Nat. Rev. Cancer 6 4 2006 259 269
151. Y. Pang, C.Y. Young, and H. Yuan MicroRNAs and prostate cancer Acta Biochimica Biophysica Sinica 42 6 2010 363 369
152. T. Sun, X. Wang, H. He, C. Sweeney, S. Liu, M. Brown, and et al. MiR-221 promotes the development of androgen independence in prostate cancer cells via downregulation of HECTD2 and RAB1A Oncogene 33 21 2014 2790 2800
153. V. Coppola, R. De Maria, and D. Bonci MicroRNAs and prostate cancer Endocrine-related Cancer 17 1 2010 F1 F17
154. A. Watahiki, Y. Wang, J. Morris, K. Dennis, H.M. O'Dwyer, M. Gleave, and et al. MicroRNAs Associated with Metastatic Prostate Cancer 2011 e24950